[Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].
Ferrer Cañabate
J
J
Tovar
I
I
Martínez
P
P
D000818:Animals; D016723:Bone Remodeling / Q000502:physiology*; D001842:Bone and Bones / Q000502:physiology*; D002352:Carrier Proteins / Q000502:physiology*; D016207:Cytokines / Q000502:physiology*; D006023:Glycoproteins / Q000502:physiology*; D006801:Humans; D008024:Ligands; D008562:Membrane Glycoproteins / Q000502:physiology*; D010010:Osteoclasts / Q000502:physiology*; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology*; D018124:Receptors, Tumor Necrosis Factor
D002352:Carrier Proteins; D016207:Cytokines; D006023:Glycoproteins; D008024:Ligands; D008562:Membrane Glycoproteins; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C505686:TNFRSF11A protein, human; C506030:TNFRSF11B protein, human; C505688:TNFSF11 protein, human